Epidiolex rollout: $32,500 list price spurs critics as first cannabis drug hits shelves

GW Pharma growing area for CBD Epidiolex
GW Pharma growing areas in England with cannabis plants used for the first FDA-approved CBD drug Epidiolex, launching today. (GW Pharmaceuticals)

It’s official—the first FDA approved CBD product is on the market. GW Pharmaceuticals announced this morning that its cannabinoid Epidiolex, approved in the treatment of two rare forms of epilepsy, is now available by prescription. However, it may already be facing its first stumbling block with its price tag.

Epidiolex has racked up angry social media comments since August when it announced its list price as $32,500 per year—with a new surge following today’s news. GW Pharma has been quick to point out that the drug is a rare disease therapy specifically approved to treat seizures associated with Lennox-Gastaut and Dravet syndromes, and its pricing is in line with similar FDA-approved anti-epileptics.

RELATED: Sunovion highlights epilepsy heroes in reupped awareness campaign

3-Day Conference

6th Promotional Review Committee Compliance & Best Practices Conference

The leading U.S. event devoted to building the skills, speed and teamwork of your promotional review committee members will take place May 15–17, 2019 in Chicago. The conference is set to bring together more than 75 professionals to ensure your PRC is prepared to generate, collect and constructively act on expert comments for your entire drug and device portfolio.

GW has also set up a patient support program which includes help lowering out-of-pocket costs and even no cost for some patients. It's working with payers and in its last financial call in August said it had presented plans that would “cover over 80% of commercial covered lives in the United States,” according to a Seeking Alpha transcript. It estimated out-of-pocket costs to average less than $10 per month for Medicaid patients and less than $35 per month on average for commercial patients.

The pricing blowback is part of what has been GW Pharma’s marketing challenge from the beginning—show doctors and potential patients that the FDA-approved Epidiolex is vastly different from the cannabis-shop oil people have come to know through some state’s legalization of marijuana in the U.S.

Speaking to FiercePharma earlier this month about launch plans, Stephen Schultz, VP of investor relations, said GW has hired 66 neurology sales representatives who will target some 5,000 epilepsy specialists with a message to trust the science and rigor behind the only FDA-approved CBD.

RELATED: Kalytera's cannabis-based GVHD drug gathers steam

Epidiolex was initially approved in June, but had to wait until September for the Drug Enforcement Agency to figure out how to handle the plant-derived cannabidiol CBD. The good news for GW was a rescheduling from a Schedule I drug—others in that class include heroin and marijuana—to a Schedule V, the class considered with the least potential for abuse; it includes medicines such as Robitussin AC and Lyrica.

Epidiolex’ approval and now launch has been seen as a positive sign for other companies working toward FDA approval for their own CBD medicines, including AXIM Biotechnologies and Cure Pharmaceutical.

Suggested Articles

The FDA has handed down its decision against Sanofi and Lexicon's Zynquista.

Analysts with Cortellis expect seven blockbuster drug launches in markets across the world this year. AbbVie's upadacitinib leads the pack.

The new Alcon shares will be listed on the Swiss Exchange and the New York Stock Exchange on April 9 under the ticker “ALC.”